{"doi":"10.1093/ibd/izaf086","title":"18F-FAPI PET/CT for Early Detection and Severity Assessment of Intestinal Fibrosis in a Mouse Model","abstract":"<jats:title>Abstract</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>To investigate the feasibility of using 18F-fibroblast activation protein (FAP) inhibitor positron emission tomography/computed tomography (18F-FAPI PET/CT) to detect intestinal fibrosis in its early stages and identify its severity in a mouse model.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>A dextran sulfate sodium (DSS)-induced mouse model of intestinal fibrosis was established. To detect pro-inflammatory cytokines and histopathology, blood and intestinal lesion samples were collected after 18F-FAPI PET/CT scanning (3.7 MBq/mice) at 3, 6, 9, and 12 weeks post-initial exposure to DSS. Correlation and diagnostic efficacy were explored between 18F-FAPI uptake and FAP expression or fibrosis score in early, late, and entire stages of intestinal fibrosis.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>18F-FAPI uptake was positively correlated with FAP expression throughout entire stages of intestinal fibrosis (r = 0.90). However, a weak correlation between 18F-FAPI uptake and fibrosis score (r = 0.49), and moderate diagnostic performance of 18F-FAPI PET for fibrotic severity (area under the receiver-operating characteristic curve [AUC] = 0.79) were found throughout the entire stages. Interestingly, in the early stages, 18F-FAPI PET effectively distinguished the degree of intestinal fibrosis (AUC = 0.95), and was strongly correlated with fibrosis score (r = 0.89). In the late stages, the diagnostic efficacy (AUC = 0.46) and correlation (r = −0.20) drastically decreased.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>As Crohn’s disease (CD) with intestinal fibrosis progresses, 18F-FAPI uptake is high in the early stages and then gradually decreases. Activated fibroblasts appear more frequently in the early stages of intestinal fibrosis indicates that 18F-FAPI PET has a great potential for early identification of intestinal fibrosis and provides new insights into treatment decision-making in CD patients.</jats:p>\n               </jats:sec>","journal":"Inflammatory Bowel Diseases","year":2025,"id":649903,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1694419,"name":"Jiantao Ran","orcid":null,"position":1,"is_corresponding":false},{"id":1048848,"name":"Xinyue Hu","orcid":"0009-0006-2685-951X","position":2,"is_corresponding":false},{"id":1694422,"name":"Chaoqun Lv","orcid":null,"position":3,"is_corresponding":false},{"id":1694424,"name":"Jianping You","orcid":null,"position":4,"is_corresponding":false},{"id":829903,"name":"Duo Sun","orcid":null,"position":5,"is_corresponding":false},{"id":1694427,"name":"Leiyue Chen","orcid":null,"position":6,"is_corresponding":false},{"id":589968,"name":"Yi Tang","orcid":"0009-0001-5425-8600","position":7,"is_corresponding":false},{"id":1694429,"name":"Hongqing Li","orcid":null,"position":8,"is_corresponding":false},{"id":1694431,"name":"Daoxi Hu","orcid":null,"position":9,"is_corresponding":false},{"id":1192684,"name":"Kaijun Liu","orcid":"0000-0001-5882-1328","position":10,"is_corresponding":false},{"id":543871,"name":"Dongfeng Chen","orcid":"0000-0003-1263-2374","position":11,"is_corresponding":false},{"id":259393,"name":"Xiao Chen","orcid":"0000-0002-1432-268X","position":12,"is_corresponding":false},{"id":1694417,"name":"Weicheng Zhou","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"18F-FAPI PET/CT for Early Detection and Severity Assessment of Intestinal Fibrosis in a Mouse Model","abstract":"<jats:title>Abstract</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>To investigate the feasibility of using 18F-fibroblast activation protein (FAP) inhibitor positron emission tomography/computed tomography (18F-FAPI PET/CT) to detect intestinal fibrosis in its early stages and identify its severity in a mouse model.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>A dextran sulfate sodium (DSS)-induced mouse model of intestinal fibrosis was established. To detect pro-inflammatory cytokines and histopathology, blood and intestinal lesion samples were collected after 18F-FAPI PET/CT scanning (3.7 MBq/mice) at 3, 6, 9, and 12 weeks post-initial exposure to DSS. Correlation and diagnostic efficacy were explored between 18F-FAPI uptake and FAP expression or fibrosis score in early, late, and entire stages of intestinal fibrosis.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>18F-FAPI uptake was positively correlated with FAP expression throughout entire stages of intestinal fibrosis (r = 0.90). However, a weak correlation between 18F-FAPI uptake and fibrosis score (r = 0.49), and moderate diagnostic performance of 18F-FAPI PET for fibrotic severity (area under the receiver-operating characteristic curve [AUC] = 0.79) were found throughout the entire stages. Interestingly, in the early stages, 18F-FAPI PET effectively distinguished the degree of intestinal fibrosis (AUC = 0.95), and was strongly correlated with fibrosis score (r = 0.89). In the late stages, the diagnostic efficacy (AUC = 0.46) and correlation (r = −0.20) drastically decreased.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>As Crohn’s disease (CD) with intestinal fibrosis progresses, 18F-FAPI uptake is high in the early stages and then gradually decreases. Activated fibroblasts appear more frequently in the early stages of intestinal fibrosis indicates that 18F-FAPI PET has a great potential for early identification of intestinal fibrosis and provides new insights into treatment decision-making in CD patients.</jats:p>\n               </jats:sec>","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40349210","pmcid":null,"openalex_id":"https://openalex.org/W4410269165","authors":[],"funders":[{"funder_name":"Chongqing Science and Health Joint Medical Research Project-Young and Middle-aged High-level Talent Project","grant_id":"2023GDRC002","title":null},{"funder_name":"Natural Science Foundation of Chongqing","grant_id":"2024NSCQ-MSX3234","title":null},{"funder_name":"Science and Technology Innovation Ability Enhancement Project of Army Medical University","grant_id":"2022XJS29","title":null},{"funder_name":"Science and Technology Innovation Ability Enhancement Project of Army Medical University","grant_id":"2023XLC06","title":null},{"funder_name":"Chongqing Clinical Research Centre of Imaging and Nuclear Medicine","grant_id":"CSTC2015YFPT-gcjsyjzx0175","title":null}],"total_grants":5,"fwci":2.5551,"citation_percentile":0.90460552,"influential_citations":0,"citation_trend":[{"year":2025,"count":2},{"year":2026,"count":3}],"oa_status":"closed","license":"https://academic.oup.com/pages/standard-publication-reuse-rights","oa_locations":[{"url":"https://academic.oup.com/ibdjournal/article-pdf/31/7/2019/63142609/izaf086.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/ibd/izaf086","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40349210","host_type":"repository"}],"fields_of_study":["Peptidase Inhibition and Analysis","Connective tissue disorders research","Orthopedic Infections and Treatments","Animals","Mice","Positron Emission Tomography Computed Tomography","Fibrosis","Disease Models, Animal","Severity of Illness Index","Dextran Sulfate","Early Diagnosis","Male","Mice, Inbred C57BL","Fluorine Radioisotopes","Membrane Proteins","Intestines","Serine Endopeptidases","Colitis","Female","Radiopharmaceuticals","Gelatinases","Endopeptidases","Fibroblast Activation Protein Alpha"],"mesh_terms":["Positron Emission Tomography Computed Tomography","Fibroblast Activation Protein Alpha","Animals","Colitis","Disease Models, Animal","Female","Fibrosis","Fluorine Radioisotopes","Intestines","Male","Membrane Proteins","Mice, Inbred C57BL","Endopeptidases","Serine Endopeptidases","Severity of Illness Index","Dextran Sulfate","Gelatinases","Radiopharmaceuticals","Early Diagnosis","Mice"],"keywords":["Fibrosis","Medicine","Pathology","Histopathology","Receiver operating characteristic","Fibroblast","Gastroenterology","Fibroblast activation protein, alpha","Nuclear medicine","Internal medicine","Chemistry","Cancer","Positron emission tomography","Crohn’s Disease","18F-fibroblast Activation Protein Inhibitor","Mouse Model Of Intestinal Fibrosis"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T04:29:34.590818Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}